A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome

PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: George, Charles F. P., Feldman, Neil, Zheng, Yanping, Steininger, Teresa L., Grzeschik, Susanna M., Lai, Chinglin, Inhaber, Neil
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2010
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3098358/
https://ncbi.nlm.nih.gov/pubmed/20082240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11325-009-0320-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge